Virtual Library

Start Your Search

F. Navarro



Author of

  • +

    P1.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 233)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Biology, Pathology, and Molecular Testing
    • Presentations: 1
    • +

      P1.04-032 - Clinical and Pathological Characterization of Long-Term Survivors with Advanced Non-Small Cell Lung Cancer: A Multicenter Experience in Madrid (ID 378)

      09:30 - 09:30  |  Author(s): F. Navarro

      • Abstract
      • Slides

      Background:
      Long-time survival is an important goal in NSCLC treatment. However, in patients (pts) with wild type EGFR and non translocated ALK (EGFRwt/ALKnt) advanced disease, median survival at diagnosis is around 9-14 months and long time survivors (LTS) constitute a very small proportion of these patients. The aim of our research was to explore the clinical-pathological characteristics of a population of EGFRwt/ALKnt LTS with an overall survival (OS) of at least 36 months, with the purpose to identify which clinical-pathological features could help to identify a better outcome in advanced NSCLC.

      Methods:
      We analyzed retrospectively data from patients diagnosed of EGFRwt/ALKnt advanced NSCLC with an OS of at least 36 months and treated in 8 institutions from Madrid (Spain). All these patients were selected in a period of 10 years (January 2002 to 2012). We analyzed clinical-pathological characteristics (age, sex, ECOG, stage IIIB vs IV, histology, smoking status, diabetes and vascular disease, weight loss >10%, symptoms at diagnosis and sites of metastasis), laboratory parameters (LDH and haemoglobin levels) and type of treatment administered (platinum based treatment, metasectomies, number of chemotherapy lines, maintenance, grade 4 toxicity as well as metformine intake). Finally, data from PFS and OS were also collected.

      Results:
      Among all patients diagnosed with EGFRwt/ALKnt NSCLC and treated in 8 institutions in 10 years, we identified 93 pts with an OS of at least 36 months. 55 pts (60%) were older 65 years, 67 pts (71%) male and 85 pts (91 %) were smokers/former smokers. Comorbidities (diabetes and vascular disease) were infrequent: 7pts (7%) and 13 pts (14%), respectively. Adenocarcinoma was most common pathological subgroup (60 pts, 65%) followed by squamous (21 pts, 22%), large cell carcinoma (7, 7%) and “other histologies” (6 pts, 6%). The majority of them, had a good PS; ECOG 0 32 pts (34%) and 1 57 pts (61%). A minority of patients had weight loss greater than 10% at presentation (12 pts, 14%). Most frequent symptoms were cough (41 pts, 44%), followed by pain (34 pts, 36%), dyspnea (25 pts, 27%) and haemoptysis (9 pts, 9%). LDH and haemoglobin leves were normal in the majority (65 pts, 70% and 72 pts, 77%, respectively). On the other hand, metformin intake was uncommon (16 pts, 17%). One or two metastatic sites at diagnosis were described in 44 pts, 47% and 29 pts, 31%, respectively and only 13 pts (14%) had brain metastasis (mts) and 5 (5%) adrenal mts. First-line chemotherapy based in platinum was administrated in 92 pts (98%), however, maintenance therapy only in 41 pts (44%). Local treatment (metasectomies +/-RT), was done in 35 pts (38 %). Grade 4 toxicity was detected in 7 pts (7%). Finally, we estimated a median PFS of 13.4 months and median OS of 40.5 months

      Conclusion:
      To our knowledge, this is the largest multicenter serie reported of very long-term survivors (OS >36 months) with with EGFRwt/ALKnt advanced NSCLC. This study includes an exhaustive clinical and pathological analysis of this specific population. In this moment, we are carrying out a comprehensive molecular analysis

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.